A Medical Device Daily
Non-Invasive Monitoring Systems (North Bay Village, Florida) reported that the U.S. Patent Office issued Patent 7,228,576 on June 12 titled, “Reciprocating movement platform for the external addition of pulses to the fluid channel of a subject.”
The company said that the patent is a continuation of U.S. patent 7,311,346 issued in 2006, which dealt with its motion platform applications in human subjects. The new patent discloses motion platform applications in horses and further protects the value of the company’s flagship products (AT-101 and Exer-Rest) for therapeutic and diagnostic applications that have already been published in peer-reviewed research studies as well as for future products and applications.”
Dr. Marvin Sackner, chairman as well as co-inventor with D. Michael Inman, said: “It is well established that many beneficial effects of exercise relate to release of mediators into the circulation. The technology disclosed in this patent is a non-invasive, drug-free means to cause release of these beneficial mediators to approximately the same blood levels as exercise in resting animals. Such mediators include nitric oxide, prostacyclin, and tissue plasminogen activator (tPA), among others. Research findings in large animal models corroborating this action have been published by Dr. Jose Adams and associates at Mount Sinai Medical Center of Greater Miami.”
“Our motion platform has been designed to support a standing horse held in position with a sling such that its body is passively moved repetitively head to tail over a period of 30 to 45 minutes. Such motion adds smaller amplitude pulses to the natural pulse at the frequency of the platform movements thereby providing beneficial effects due to release if the same mediators that occur during exercise.”
In other patent news: Aethlon Medical (San Diego) reported that Patent No. 7,226,429 has been issued to Aethlon Medical by the U.S. Patent and Trademark Office (USPTO). The patent, “Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis,” is integral to Aethlon’s intellectual property portfolio as it defines methods that allow the Aethlon Hemopurifier to selectively capture a broad-spectrum of viruses from blood, the company said.
Aethlon Medical is the developer of the Hemopurifier, a first-in-class medical device to treat infectious disease. The Hemopurifier is a platform technology targeted to be a broad-spectrum treatment solution for drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV).
Collaborative studies to demonstrate utility of the Hemopurifier are being conducted with researchers at the Government of India’s National Institute of Virology (NIV), the Centers for Disease Control and Prevention (Atlanta), the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID; Fort Detrick, Maryland), and The Southwest Foundation for Biomedical Research (SFBR; San Antonio).